UNSPSC 51162106: Ethambutol/isoniazid/pyrazinamide/rifampicin

Definition: This classification is for a combination medication for TB treatment. The first component, ETHAMBUTOL, has US FDA Unique Ingredient Identifier of 8G167061QZ. ETHAMBUTOL is an International Non-Proprietary Name or INN. The second component, ISONIAZID, has US FDA Unique Ingredient Identifier of V83O1VOZ8L. ISONIAZID is an International Non-Proprietary Name or INN. The third component, PYRAZINAMIDE, has US FDA Unique Ingredient Identifier of 2KNI5N06TI. PYRAZINAMIDE is an International Non-Proprietary Name or INN.

The fourth component, RIFAMPICIN, has US FDA Unique Ingredient Identifier of VJT6J7R4TR. RIFAMPICIN is an International Non-Proprietary Name or INN.

UNSPSC 51162106 Ethambutol/isoniazid/pyrazinamide/rifampicin (Commodity) does not align with recent state and local procurement activity in the available record. The code names a specific combination tuberculosis medication, yet the opportunities posted under this code or closely related pharmaceutical classifications involve medical oxygen rentals, naloxone, biometric testing supplies, forensic drug standards, generic multi-source pharmaceuticals, and operational health clinic services—none of which are the named combination drug. The recent solicitations include the City of Little Rock Fire Department's ITQ for medical oxygen cylinder rental (January 2026), Seminole County's procurement of naloxone and drug deactivation systems (June 2026), and the Minnesota Multistate Cooperative Purchasing Alliance' RFP for generic multi-source pharmaceuticals and OTC products (January 2026), but none target the specific ethambutol/isoniazid/pyrazinamide/rifampicin combination.

The mismatch between the Commodity code's nominal scope and the actual work being bought under related pharmaceutical classifications reflects a common indexing issue in state and local procurement systems. Geographic activity spans Florida, Texas, Arkansas, Minnesota, and multi-state cooperative vehicles, but tuberculosis-specific medications do not appear as a distinct procurement category in the recent posting cycle. If pursuing pharmaceutical distribution or hospital supply chains at state and local level, monitor broader generic-drug and OTC-products contracts—such as MMCAP's multi-source pharmaceutical vehicle or Seminole County's public health acquisitions—rather than this narrowly defined combination-drug code.